VAMP7 (Vesicle-Associated Membrane Protein 7), also known as TI-VAMP (Tetratricopeptide-Vesicle Associated Membrane Protein), is a member of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment Protein Receptor) family. Located on chromosome Xq28, VAMP7 is a longin domain-containing v-SNARE protein that plays critical roles in intracellular vesicle trafficking, including regulated exocytosis, endocytosis, lysosomal fusion, and autophagy. VAMP7 is essential for synaptic vesicle release, neuronal development, and has been implicated in Alzheimer's disease, Parkinson's disease, and Hermansky-Pudlak syndrome.
| Attribute |
Value |
| Gene Symbol |
VAMP7 |
| Full Name |
Vesicle-Associated Membrane Protein 7 |
| Alternative Names |
TI-VAMP, SYBL1 |
| Chromosomal Location |
Xq28 |
| NCBI Gene ID |
6845 |
| Ensembl ID |
ENSG00000125459 |
| UniProt ID |
Q9UBW5 |
| OMIM |
300301 |
| Protein Class |
SNARE protein; Vesicle trafficking |
| Associated Diseases |
Alzheimer's disease, Parkinson's disease, Hermansky-Pudlak syndrome |
The VAMP7 gene spans approximately 35 kb and consists of 13 exons encoding a 219-amino acid protein. The gene is located on the X chromosome and undergoes alternative splicing to generate multiple isoforms with tissue-specific expression patterns.
VAMP7 contains several functional domains:
-
N-terminal Longin Domain — The defining feature of VAMP7; this 120-amino acid domain regulates SNARE complex formation through autoinhibition. The longin domain maintains VAMP7 in a "closed" conformation, preventing premature SNARE interactions.
-
SNARE Motif — The central region (amino acids 1-60) contains the characteristic heptad repeat sequences that form the SNAREpin during membrane fusion.
-
Transmembrane Domain — The C-terminal region (amino acids 180-219) anchors VAMP7 to vesicle membranes.
The unique longin domain distinguishes VAMP7 from other VAMP family members (VAMP1, VAMP2) and contributes to its specialized functions in regulated exocytosis and lysosomal trafficking.
VAMP7 functions as a v-SNARE (vesicle SNARE) in intracellular membrane fusion events:
- SNARE pairing — VAMP7 forms trans-SNARE complexes with target SNAREs (t-SNAREs) like syntaxins
- Membrane fusion — The SNAREpin brings vesicle and target membranes together, driving fusion
- Specificity — VAMP7 interacts with specific t-SNAREs, determining trafficking specificity
VAMP7 is involved in several exocytic pathways:
- Synaptic vesicle release — VAMP7 contributes to neurotransmitter release at synapses
- Lysosomal exocytosis — VAMP7 mediates Ca²⁺-triggered lysosomal fusion with the plasma membrane
- Secretory granule release — VAMP7 participates in regulated secretion from specialized granules
VAMP7 plays critical roles in endosomal system function:
- Endolysosomal fusion — VAMP7 mediates fusion between late endosomes and lysosomes
- Autophagosome-lysosome fusion — VAMP7 is required for autophagic flux
- Cargo trafficking — VAMP7 ensures proper delivery of cargo to degradation compartments
VAMP7 is a key player in autophagy:
- Autophagosome formation — VAMP7 participates in early autophagic events
- Autophagosome-lysosome fusion — Essential for the final step of autophagy
- Lysosomal function — VAMP7 maintains lysosomal membrane integrity
In neurons, VAMP7 supports:
- Synaptic vesicle cycling — VAMP7 participates in synaptic vesicle exocytosis and recycling
- Neurite outgrowth — VAMP7-mediated trafficking supports axonal and dendritic growth
- Dendritic spine formation — VAMP7 contributes to synaptic junction assembly
VAMP7 is expressed throughout the brain:
- Cerebral cortex — Pyramidal neurons and interneurons
- Hippocampus — CA1-CA3 regions, dentate gyrus (memory)
- Cerebellum — Purkinje cells
- Substantia nigra — Dopaminergic neurons
- Hippocampal neurons — High expression in synaptic regions
VAMP7 expression in synapses and key neurodegeneration-relevant regions explains its disease associations.
VAMP7 activity is tightly regulated:
- Longin domain autoinhibition — The longin domain keeps VAMP7 inactive until needed
- Calcium sensing — Ca²⁺ influx triggers VAMP7-mediated exocytosis
- Phosphorylation — Kinases modulate VAMP7 SNARE assembly
- Interaction with accessory proteins — Munc13, Munc18, and other regulators control VAMP7
VAMP7 is implicated in Alzheimer's disease through:
- Amyloid-beta secretion — VAMP7 participates in Aβ release through exocytosis
- Neuronal trafficking disruption — VAMP7 dysfunction affects axonal transport
- Lysosomal impairment — VAMP7 deficiency contributes to lysosomal dysfunction
- Synaptic loss — VAMP7 alterations affect synaptic integrity
VAMP7 may contribute to Parkinson's disease through:
- Alpha-synuclein secretion — VAMP7-mediated exocytosis contributes to α-syn spread
- Lysosomal dysfunction — VAMP7 alterations affect autophagic-lysosomal pathway
- Dopaminergic neuron vulnerability — VAMP7 is expressed in substantia nigra neurons
- Membrane trafficking — VAMP7 dysfunction affects dopamine release
VAMP7 mutations cause a form of HPS:
- Lysosomal trafficking defects — Impaired lysosome-related organelle function
- Oculocutaneous albinism — Melanocyte dysfunction
- Bleeding diathesis — Platelet dense granule defects
- Immunodeficiency — Immune cell dysfunction
- Amyotrophic lateral sclerosis — VAMP7 in motor neuron function. Altered VAMP7 expression in ALS spinal cord.
- Huntington's disease — Altered VAMP7 in striatal neurons. VAMP7 dysfunction may contribute to vesicular trafficking defects.
- Neuronal ceroid lipofuscinoses — Lysosomal trafficking defects. VAMP7 affects lysosome-related organelle function.
VAMP7 participates in SNARE complex formation:
- v-SNARE recruitment — VAMP7 localizes to vesicle membranes
- t-SNARE binding — VAMP7 pairs with syntaxins and SNAPs
- SNAREpin formation — Four-helix bundle forms between v- and t-SNAREs
- Membrane fusion — Energy released drives fusion
- Disassembly — NSF/α-SNAP disassembles the complex
¶ Longin Domain Regulation
The longin domain controls VAMP7 activity:
- Autoinhibition — The longin domain binds the SNARE motif, preventing assembly
- Activation — Triggering events (Ca²⁺, phosphorylation) release inhibition
- Interaction specificity — The longin domain determines partner selection
- Regulation by phosphorylation — Casein kinases and other kinases modulate VAMP7
VAMP7 mediates Ca²⁺-triggered exocytosis:
- Synaptotagmin binding — VAMP7 interacts with synaptotagmin VII
- Calcium sensing — Ca²⁺ influx triggers VAMP7-mediated fusion
- Fusion pore dynamics — VAMP7 regulates fusion pore formation
VAMP7 is implicated in Alzheimer's disease:
Amyloid-beta secretion: VAMP7 participates in Aβ release through exocytosis. Amyloid precursor protein (APP) processing involves VAMP7-mediated vesicular trafficking.
Neuronal trafficking disruption: VAMP7 dysfunction affects axonal transport. Impaired VAMP7 leads to cargo accumulation and trafficking jams.
Lysosomal impairment: VAMP7 deficiency contributes to lysosomal dysfunction. Lysosomal cathepsin activity is affected in AD.
Synaptic loss: VAMP7 alterations affect synaptic integrity. Synaptic vesicle numbers are reduced with VAMP7 dysfunction.
Tau pathology connections: VAMP7 may interact with tau pathways. Both proteins are involved in vesicular trafficking.
VAMP7 may contribute to Parkinson's disease:
Alpha-synuclein secretion: VAMP7-mediated exocytosis contributes to α-syn spread. Extracellular α-syn can be taken up by neighboring neurons.
Lysosomal dysfunction: VAMP7 alterations affect autophagic-lysosomal pathway. PINK1/Parkin mitophagy intersects with VAMP7 function.
Dopaminergic neuron vulnerability: VAMP7 is expressed in substantia nigra neurons. Unique vulnerability of these neurons may involve trafficking defects.
Membrane trafficking: VAMP7 dysfunction affects dopamine release. Synaptic vesicle dynamics are impaired.
VAMP7 mutations cause a form of HPS:
- Lysosomal trafficking defects — Impaired lysosome-related organelle function
- Oculocutaneous albinism — Melanocyte dysfunction
- Bleeding diathesis — Platelet dense granule defects
- Immunodeficiency — Immune cell dysfunction
- Pulmonary fibrosis — Lung involvement in some cases
VAMP7 is a potential therapeutic target for:
Neurodegenerative diseases: Modulating VAMP7 may improve neuronal trafficking. Enhancing VAMP7 function could protect synaptic function.
Lysosomal disorders: VAMP7-targeted approaches could treat HPS. Gene therapy to restore VAMP7 function.
Cancer: VAMP7 inhibitors may block tumor exocytosis. VAMP7 is overexpressed in some cancers.
- SNARE modulators — Develop compounds that enhance or inhibit VAMP7 SNARE activity
- Calcium channel modulators — Affect VAMP7-mediated exocytosis
- Gene therapy — Restore VAMP7 function in deficiency states
- Small molecule enhancers — Improve VAMP7 trafficking function
- VAMP7 expression as marker of synaptic health
- CSF VAMP7 levels in neurodegeneration
- VAMP7 genetic variants as risk modifiers
- How does VAMP7 dysfunction specifically contribute to different neurodegenerative diseases?
- Can VAMP7 function be enhanced therapeutically?
- What is the relationship between VAMP7 and specific protein aggregates?
- How do VAMP7 variants affect disease risk?
- VAMP7 in tau propagation: Does VAMP7 mediate spread of tau pathology?
- VAMP7 and mitochondrial quality control: Connections to mitophagy
- VAMP7 in neuroinflammation: Role of exosomal release
¶ Longin Domain Structure
The N-terminal longin domain of VAMP7 is approximately 120 amino acids and adopts a fold resembling the LONGIN domain family structure. This domain serves critical regulatory functions:
The longin domain is unique to VAMP7 and related longin-domain containing VAMPs (VAMP4, VAMP5), distinguishing them from classic VAMPs like VAMP1/2/3.
¶ SNARE Motif and Transmembrane Domain
The SNARE motif (amino acids 1-60) contains:
- Heptad repeats: Characteristic coiled-coil forming sequences
- Ionic zero layer: Central arginine (R) residue critical for complex formation
- Hypervariable region: Determines pairing specificity
The transmembrane domain (amino acids 180-219):
- Single α-helix: Spans the membrane
- Membrane anchoring: Essential for vesicle localization
- Palmitoylation: Some isoforms show additional lipid modifications
VAMP7 participates in multiple stages of synaptic vesicle cycling:
- Vesicle priming: VAMP7 is recruited to docked vesicles
- Calcium-triggered fusion: Synaptotagmin VII senses Ca²⁺ entry
- SNARE complex formation: VAMP7 pairs with syntaxin-1 and SNAP-25
- Fusion pore opening: Initial release of neurotransmitter
- Endocytosis: VAMP7 retrieved for recycling
Unlike VAMP2 (synaptobrevin-2), VAMP7 contributes to a distinct pool of synaptic vesicles.
VAMP7 function is modulated by neuronal activity:
- Phosphorylation: CaMKII and PKA phosphorylate VAMP7
- Calcium sensitivity: Direct Ca²⁺ binding enhances fusion
- Trafficking dynamics: Activity-dependent mobilization of VAMP7 pools
VAMP7 contributes to autophagosome biogenesis:
- Isolation membrane: VAMP7 localizes to nascent autophagosomes
- ER contact sites: Coordinates with ER for membrane expansion
- Atg proteins: Interacts with Atg14 and other autophagy proteins
The final step of autophagy requires VAMP7-mediated fusion:
- Autophagosome maturation: Late autophagosomes acquire VAMP7
- Lysosomal recruitment: VAMP7 on autophagosomes engages lysosomal SNAREs
- SNARE complex assembly: Forms the fusion machinery
- Membrane fusion: Autophagic cargo delivered to lysosomes
Neuronal autophagy is particularly important due to:
- Post-mitotic nature: Neurons cannot dilute protein aggregates
- High metabolic demand: Requires efficient clearance mechanisms
- Axonal complexity: Autophagy needed in distant terminals
VAMP7 dysfunction impairs autophagic flux, contributing to neurodegeneration.
Developing VAMP7-targeted therapeutics faces challenges:
- SNARE complex modulators: Affects multiple SNARE proteins
- Calcium channel modifiers: Alters exocytosis broadly
- Phosphorylation inhibitors: Targets upstream regulators
VAMP7 gene therapy shows promise:
- AAV vectors: Deliver functional VAMP7 to neurons
- CRISPR editing: Correct pathogenic mutations
- RNAi: Reduce harmful overexpression in certain contexts
VAMP7 as a biomarker:
- CSF measurement: VAMP7 cleavage products in disease
- Expression studies: Altered VAMP7 in neurodegenerative brains
- Genetic variants: SLC48A1 polymorphisms and disease risk
In substantia nigra pars compacta neurons:
- High VAMP7 expression
- Critical for dopamine vesicle trafficking
- Affected in PD models
VAMP7 in hippocampal circuits:
- Regulates synaptic plasticity
- Important for memory formation
- Altered in AD models
Cortical VAMP7:
- Participates in excitatory neurotransmission
- Controls dendritic vesicle trafficking
- Contributes to cortical connectivity
¶ VAMP7 and Other Neurodegeneration Genes
VAMP7 intersects with multiple PD genes:
- LRRK2: Modulates VAMP7 trafficking
- GBA: Lysosomal function affects VAMP7
- SNCA: Alpha-synuclein impairs VAMP7 function
- PINK1/Parkin: Mitophagy pathways intersect
VAMP7 participates in cellular networks:
- SNARE machinery: Core fusion proteins
- Autophagy-lysosome pathway: Final degradation step
- Endolysosomal system: Intracellular trafficking
- VAMP7 knockout cells: Loss-of-function studies
- Patient-derived iPSCs: Neurons with VAMP7 variants
- Overexpression systems: Gain-of-function analysis
- VAMP7 knockout mice: Show partial viability
- Conditional knockouts: Brain-specific deletion
- Disease models: Transgenic PD/AD backgrounds
- SNARE complex reconstitution: Purified components
- Live-cell imaging: VAMP7 trafficking dynamics
- Cryo-EM: High-resolution SNARE structures
- Disease specificity: Why are certain neurons vulnerable to VAMP7 dysfunction?
- Therapeutic window: Can we selectively enhance VAMP7 without disrupting other SNAREs?
- Biomarker validation: Is VAMP7 a reliable disease biomarker?
- Combination therapy: Can VAMP7 modulation enhance other treatments?
- Structural studies: High-resolution VAMP7 structures
- Single-cell analysis: Neuron-type specific functions
- Clinical translation: Biomarker and therapeutic development